Bivalirudin Versus Heparin Monotherapy in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary
1Department of Cardiology, Tang Du Hospital, Air Force Medical University, Shaanxi, China.
Insights
Bivalirudin plus post-PCI infusion significantly reduced net adverse clinical events (NACEs), major adverse cardiovascular events (MACEs), and in-stent thrombosis (ISTs) in ST-segment elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PCI). This approach was safer and more effective than heparin monotherapy.
Area of Science:
- Cardiology
- Interventional Cardiology
- Pharmacology
Background:
- ST-segment elevation myocardial infarction (STEMI) is a critical condition requiring prompt reperfusion therapy.
- Primary percutaneous coronary intervention (PCI) is the preferred treatment for STEMI.
- Anticoagulation strategies during and after primary PCI are crucial for patient outcomes.
Purpose of the Study:
- To compare the safety and efficacy of bivalirudin with post-PCI infusion versus heparin monotherapy in STEMI patients undergoing primary PCI.
- To evaluate the impact of these anticoagulation strategies on key clinical outcomes.
Main Methods:
- A systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted.
- Searched databases included PubMed, EMBASE, Cochrane Library, and Web of Science.
- Outcomes assessed included net adverse clinical events (NACEs), major adverse cardiovascular events (MACEs), in-stent thrombosis (IST), and bleeding events (BARC types 2, 3, 5).
Main Results:
- The analysis included four RCTs with 10,695 events.
- Bivalirudin plus post-PCI infusion significantly reduced NACEs (RR 0.84, P=0.009), MACEs (RR 0.82, P=0.04), and ISTs (RR 0.66, P<0.0001) compared to heparin.
- No significant differences were observed in all-cause death, cardiac death, stroke, MI, TVR, or BARC bleeding between the groups.
Conclusions:
- Bivalirudin with post-PCI infusion is a safer and more effective strategy than heparin monotherapy for STEMI patients undergoing primary PCI.
- This regimen significantly lowers the risk of NACEs, MACEs, and ISTs.
- It does not increase the risk of MI or TVR and may offer potential benefits in reducing stroke, death, and bleeding events.
Aims:
The present meta-analysis focused on investigating whether bivalirudin plus post-PCI infusion was safer and more effective than heparin monotherapy in patients who developed ST-segment elevation myocardial infarction (STEMI) and who underwent primary percutaneous coronary intervention (PCI).
Methods:
The PubMed, EMBASE, Cochrane Library, and Web of Science databases were systemically searched to identify randomized controlled trials (RCTs) comparing bivalirudin and heparin for treating STEMI patients who underwent primary PCI. The Cochrane quality assessment tool was used to assess the quality of the enrolled studies. The primary and secondary outcomes included net adverse clinical events (NACEs, comprising all-cause death or major bleeding), major adverse cardiovascular events (MACEs, comprising all-cause death, stroke, MI, and TVR), in-stent thrombosis (IST), and bleeding of Bleeding Academic Research Consortium (BARC) types 2, 3, and 5.
Results:
The four RCTs, comprising 10,695 events, included 5350 patients who received bivalirudin combined with post-PCI infusion and 5345 patients who received heparin monotherapy. Compared with those in the heparin group, the number of NACEs (RR 0.84, 95% CI 0.73-0.96, P = 0.009), MACEs (RR 0.82, 95% CI 0.67-0.99, P = 0.04), and ISTs (RR 0.66, 95% CI 0.49-0.91, P < 0.0001) in the bivalirudin group was significantly lower. There were no significant differences in all-cause death, cardiac death, stroke, MI, TVR, or BARC type 2, 3, or 5 bleeding between the two groups.
Conclusion:
In STEMI patients undergoing primary PCI, bivalirudin plus post-PCI infusion significantly reduced the incidence of NACEs, MACEs, and ISTs compared with heparin monotherapy, without increasing the risk of MI or TVR. Bivalirudin may also contribute to a potential reduction in stroke, death, and BARC type 2, 3, and 5 bleeding rates.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...